Skip to main content
  • IPC organised virtual training on Pharmacovigilance for NABH accredited hospitals

     IPC organised the virtual training on Pharmacovigilance for NABH Accredited Hospitals in India on 21st January 2022. The Training Programme was intended to provide a platform for the NABH-Accredited Hospitals to understand the systems and procedures involved in ADR-reporting and relevant practises.

  • CCI approves acquisition of GSK Asia

    The Competition Commission of India (CCI) approves acquisition by GlaxoSmithKline Consumer Healthcare Overseas Limited and GlaxoSmithKline Consumer Healthcare UK Trading Limited (Acquirers) of shareholding in GlaxoSmithKline Asia Private Limited (Target) under Section 31(1) of the Competition Act, 2002.

  • The government made the QR code mandatory on every bulk drug

    The government of India made the Quick Response (QR) code mandatory on every bulk drug manufactured or imported in India to curb counterfeit or spurious quality of medicines. This rule will be applicable from 1st January 2023.

    The QR code will help track and trace bulk drugs (Active pharmaceutical ingredients or APIs) during the entire supply chain. And it will ensure that the quality of APIs should not be altered.

  • Health Ministry includes Liquid Antiseptics for household use in Schedule K of Drugs rules

    ​The Ministry of Health and Family Welfare includes Liquid Antiseptics for household use in schedule K after making an amendment in the Drugs Rules, 1945. Government had released draft notification with consultation with DTAB in September 2021. These rules may be called the Drugs 2nd Amendment Rules, 2022.

  • Government to allow pharmacists to provide certain medicine without prescription

    Indian Pharmacists will soon allow the sale of certain medicines without the prescription, as per new over the counter (OTC) policy for drugs. The Drugs Technical Advisory Board (DTAB)  has approved the new OTC policy and a draft notification will soon be issued by the health ministry.

  • Molnupiravir has serious safety concern, says ICMR

    Antiviral medicine molnupiravir which recently got approval from the CDSCO in India and is being manufactured by many pharma companies, has serious safety concerns, and thus has not been included in the national COVID-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava said.

    Bhargava said the COVID-19 task force has debated twice whether to include the Molnupiravir in the COVID-19 treatment protocol but decided against it because of concerns.

  • Gujarat State Pharmacy Council becomes first paperless council of India

    ​Gujarat State Pharmacy Council (GSPC) becomes the first paperless registration council of India. GSPC is able to start all its working and various services online which includes fresh registration, renewal services, digilocker services, payment services etc. GSPC launched newly developed web portal, software, digilocker, jobportal, mobile apps and digitalization of council with the auspicious presence of Shri Rushikesh Patel, Health minister of Gujarat and Senior Hon.

  • CDSCO approves Covovax, Corbevax and Molnupiravir to fight COVID-19

    Union Health Minister Dr Mansukh Mandaviya on Tuesday, 28 December, announced that the Central Drugs Standard Control Organisation (CDSCO) had approved two more COVID-19 vaccines and COVID-19 pill for restricted emergency use in India.

    Two COVID-19 vaccines which are approved for restricted emergency use in India named Corbevax and Covovax. And Covid-19 pill from merck Molnupiravir is amongst the approved antiviral for COVID-19 in India.

  • NPPA fixed retail prices of 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations under Drugs (Prices Control) Order, 2013 based on the decision of 93rd Authority meeting dated 15.11.2021. The drug candidate Dapagliflozin and metformin extended release is included in 17 formulations out of 20 for which price fixation is applied. Dapagliflozin was patented by AstraZeneca and there are sixteen USA patents protecting this drug and one Paragraph IV challenge.

  • Effectiveness of COVISHIELD vaccine against the delta variant of SARS-CoV-2 in India

    SARS-CoV-2 has affected more than 200 million people causing more than 5 million deaths worldwide as per the WHO statistics. The rise in mutant variants of SARS-CoV-2 virus has led to concerns regarding vaccine effectiveness. Delta (B.1.617.2) variant is the predominant strain in India. The vaccination programme in India is driven largely by the Covishield vaccine (ChAdOx1 nCoV-19).

Subscribe to Government News

Search this website